Dramatic response to low-dose rivaroxaban in an Asian patient with deep vein thrombosis and pulmonary embolism  by Yamaguchi, Junji et al.
CD
t
J
T
a
b
c
a
A
R
R
A
K
D
T
P
R
W
I
f
e
a
c
r
m
w
i
C
s
o
s
a
p
h
o
1
hJournal of Cardiology Cases 8 (2013) e77–e80
Contents lists available at www.sciencedirect.com
Journal  of  Cardiology  Cases
journa l h om epage: www.elsev ier .com/ locate / j ccase
ase  Report
ramatic  response  to  low-dose  rivaroxaban  in  an  Asian  patient  with  deep  vein
hrombosis  and  pulmonary  embolism
unji  Yamaguchi  (MD)a,∗ , Kunihiko  Makino  (MD,  PhD)b , Yukiko  Kusunose  (MD)b ,  Shirika  Higa  (MD)a ,
akuro  Takagi  (MD)b,  Ken  Suzuki  (MD,  PhD)c, Tetsuo  Lee  (MD)b
Division of Internal Medicine, Toshiba General Hospital, 6-3-22 Higashi-ohi, Shinagawa-ku, Tokyo 140-8522, Japan
Division of Cardiovascular Medicine, Toshiba General Hospital, Tokyo, Japan
Division of Hematology, Toshiba General Hospital, Tokyo, Japan
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 4 February 2013
eceived in revised form 24 March 2013
ccepted 8 May 2013
eywords:
a  b  s  t  r  a  c  t
We  report  a case of deep  venous  thrombosis  and  pulmonary  embolism  treated  with  rivaroxaban  due
to warfarin  allergy.  The  patient  responded  well  to a  low  dose  of  15  mg/day.  There  has  been  a report
about  treating  patients  with  atrial ﬁbrillation  using  a  low  dose of rivaroxaban  in  Japan,  but no previous
reports  about  deep  vein  thrombosis/pulmonary  embolism.  This  case  suggests  that  rivaroxaban  could  be
an alternative  to warfarin  for the  treatment  of deep  vein thrombosis  and  pulmonary  embolism  in Japaneseeep vein
hrombosis
ulmonary embolism
ivaroxaban
arfarin
patients  with  warfarin  allergy.
<Learning  objective:  Recently,  several  new  anticoagulant  medications  have  been  released,  but  their
efﬁcacy  has  not  been  clariﬁed.  Rivaroxaban  has  shown  efﬁcacy  for  atrial ﬁbrillation,  deep  vein  thrombosis,
and  pulmonary  embolism  in  Europe  and  the  USA,  but this  has  not  been  demonstrated  in Japan.  The  present
case  suggests  that  rivaroxaban  can  improve  deep  vein  thrombosis  and  pulmonary  embolism  in  Japanese
3  Jap
patients  at  a low  dose.>
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Currently, warfarin is the most common medication employed
or the treatment of deep vein thrombosis (DVT) and pulmonary
mbolism (PE) after acute treatment with intravenous heparin
nd there have been many reports that strongly support its efﬁ-
acy [1–3]. Although several other oral anticoagulants have been
eleased, their efﬁcacy remains less certain. We  experienced dra-
atic improvement of DVT and PE in a patient who  was  allergic to
arfarin, after treatment with rivaroxaban, an anticoagulant that
s not approved for these conditions in Japan.
ase report
A 41-year-old Korean man  was referred to our hospital with
hortness of breath and pain in his right leg. The patient had devel-
ped these symptoms one week earlier and they had become more
evere over time. His medical history and family history did not
ppear to be contributory and his only medication was an antide-
ressant agent that he had been taking for two years. The patient
ad a history of smoking 10 cigarettes a day from 20 to 35 years
ld.
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Physical examination showed that his right lower limb was
swollen and reddened. Neurological examination revealed intact
cranial nerves, with preservation of comprehension and speech.
Muscle power was normal in all extremities and his deep ten-
don reﬂexes were normal. The electrocardiogram showed sinus
rhythm (58 beats/min) with right ventricular conduction delay in
leads V1–V2. Elevation of D-dimer (7.2 g/dl) and C-reactive pro-
tein (10.74 mg/dl) was detected by laboratory tests.
Contrast-enhanced computed tomography detected both DVT
in the right lower limb and PE (Fig. 1). There was diffuse thrombus
in the right common iliac vein, extending into the inferior vena cava
(IVC). There was also thrombus in the upper and lower branches of
the right main pulmonary artery.
The patient was treated by placement of an IVC ﬁl-
ter, followed by intravenous administration of monteplase
(1,600,000 units) and heparin (15,000 units/day), as well as oral
warfarin (3.75–4.00 mg/day).
Doppler ultrasound of the lower extremities was  done after
placement of the IVC ﬁlter and revealed complete obstruction
below the superﬁcial femoral vein, with mural thrombosis above
the common femoral vein.
We  adjusted the dose of warfarin by monitoring the prothrom-
bin time (international normalized ratio: INR), aiming for a range
between 2.0 and 3.0. The INR was controlled at 2.07–2.73. However,
repeat Doppler ultrasound, which was performed several times to
follow his progress, showed no improvement in the thrombosis.
vier Ltd. All rights reserved.
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aig. 1. Contrast enhanced computed tomography. (a) Thrombus in the right commo
ection). (c and d) Thrombus in the branches of the right main pulmonary artery (h
At 16 days after admission, we tried to remove the IVC ﬁlter, but
assive thrombi were detected. Therefore, removal of thrombi by
uction using the guiding sheath was performed, after which the
VC ﬁlter was taken out and then replaced in the IVC.
On day 11 of treatment with heparin and warfarin, he devel-
ped widespread erythematous papules that covered him from
ead to foot. He also complained of itching. Because a drug eruption
as considered possible, the drug-induced lymphocyte stimulation
est was done for each of the suspected medications and it was
ositive for warfarin. Accordingly, treatment with warfarin was
topped and rivaroxaban (15 mg/day) was administered instead.
ubsequently, his rash resolved slowly and the pain in his right
ower limb subsided. Activated partial thromboplastin time was
ontrolled at 31.6–59.4 in the setting of rivaroxaban.
Protein C and antithrombin III levels were low at the time of
dmission, but measurement of protein C, protein S, and antithrom-
in III is unreliable in the setting of an acute thromboembolic event.
is coagulation work-up showed no evidence of a plasminogen
bnormality, antiphospholipid antibody syndrome, systemic lupus
rythematosus, or other connective tissue diseases.
After checking that it was satisfactory by exercise tolerance
est, the patient was discharged 31 days after admission, follow-
ng improvement of the pain and swelling in his right lower limb.
n addition, the laboratory tests showed the lowering of D-dimer
1.0 g/dl) and C-reactive protein (0.03 mg/dl).Two months after discharge, contrast-enhanced computed
omography was  repeated to evaluate his progress. This showed
hat almost all thrombus had been cleared from the femoral vein
nd the pulmonary artery, with only slight residual thrombus in vein (coronal section). (b) Thrombus extending into the inferior vena cava (coronal
tal section).
the superﬁcial femoral vein (Fig. 2). The patient had no major or
minor bleeding complications while on anticoagulant therapy.
Discussion
Intravenous monteplase and heparin with oral warfarin are
the standard treatment for DVT and PE. Maintaining the INR in
the range of 2.0–3.0 is recommended from the results of a study
comparing low-intensity warfarin therapy (INR = 1.5–1.9) with
conventional therapy (INR = 2.0–3.0) [4], and a study comparing
high-intensity therapy (INR = 3.0–4.5) with conventional therapy
[5].
The reason why warfarin was  not effective for DVT and PE was
not apparent in this patient. Heparin-induced thrombocytopenia
was not complicated, for the number of platelets was not decreased
in the setting of heparin. PT-INR was controlled at 2.07–2.73, effec-
tive control for DVT and PE. However, there was a possibility that
the duration at the effective blood concentration of warfarin was
not sufﬁcient. Although PT-INR value was  2.07–2.73 at that time,
warfarin was continued for only about 17 days because of the
allergy.
In the present case, we had to abandon the use of warfarin
because of allergy, so we selected rivaroxaban as a substitute. We
chose rivaroxaban because it has demonstrated non-inferiority to
warfarin for the treatment of DVT and PE [6–8], and because it is
reported to show higher efﬁcacy than enoxaparin with no differ-
ence in safety [9].
Although rivaroxaban has not been approved for the treatment
of DVT and PE in Japan, the US Food and Drug Administration (FDA)
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Fig. 2. Contrast enhanced computed tomography. (a) Thrombus has disappeared from the right common iliac vein and inferior vena cava (coronal section). (b and c) Thrombus
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fas  disappeared from the branches of the right main pulmonary artery (horizontal 
ccepted rivaroxaban for the treatment of DVT/PE and prevention
f recurrence in November 2012. In addition, there is accumulating
vidence that activated factor X (Xa) may  represent a better target
or inhibition than activated factor II (IIa). This is based on an under-
tanding of the ampliﬁed nature of coagulation factor interactions
nd ﬁbrin formation, the need for smaller doses of an anticoag-
lant to block coagulation progression earlier in the sequence of
eactions, the evidence for incomplete suppression of thrombin
eneration with direct thrombin inhibitors, evidence for rebound
ypercoagulability with thrombin inhibitors, and clinical results
ith the indirect, parenteral, Xa inhibitor (fondaparinus), as well
s early phase II results of new oral Xa and IIa inhibitors compared
ith enoxaparin [10]. This is also a reason for using rivaroxaban for
his patient.
The FDA recommended a starting dose of 30 mg/day (15 mg
wice daily), but we employed a dose of 15 mg  once daily. In fact,
hase II studies have demonstrated that twice-daily administra-
ion of rivaroxaban achieves an earlier steady state, higher trough
evels, and better regression of thrombus after 3 weeks than once-
aily administration [11,12]. However, we based our dosage on the
eport that low-dose rivaroxaban (15 mg/day) was not inferior to
arfarin with respect to the rates of major and non-major clinically
elevant bleeding in Japanese patients with atrial ﬁbrillation, and
hat there was a marked reduction in the rate of stroke and systemic
mbolism with rivaroxaban therapy [13]. This study suggested that
ivaroxaban might be effective in Japanese patients at a lower dose
han that used for Western patients. But the J-ROCKET includes only
apanese patients, and this patient is Korean. There is the article
omparing apixaban, Xa inhibitor, with warfarin including the dif-
erence of the patient’s geographical region. From that study, then).
Japanese and the Koreans are grouped together as Asian Paciﬁc,
and their efﬁcacy is considered to be similar. Thus we selected
the study of J-ROCKET as a reference for treating this Korean
patient.
We repeated the clotting proﬁle study about two months after
the onset of DVT/PE, but found nothing speciﬁc. A study of Japanese
patients who developed DVT without apparent cause showed that
55 out of 173 subjects (32%) had at least one defect of the protein
S, protein C, or antithrombin genes [14]. This report emphasizes
that many thromboembolic mechanisms are not yet understood
and that current tests are unreliable for detection of congenital
coagulation defects.
In this case, the patient is continuing rivaroxaban to the present
day. It is because IVC ﬁlter is still placed, and the reason of form-
ing diffuse thrombus remains uncertain in this patient. We  tried
to remove the IVC ﬁlter, but diffuse thrombus made it difﬁcult,
and after removal of thrombi by suction using guiding sheath, we
once took the IVC ﬁlter out, then replaced it in the IVC. Further-
more, diffuse thrombus formed in this 41-year-old male without
apparent cause, additionally nothing speciﬁc was  identiﬁed in the
coagulation work up, and it appeared to have a great possibility
to recur. Thus we  think this patient should continue rivaroxaban
permanently.
In conclusion, we  reported an Asian patient with DVT and PE
who showed dramatic improvement when treated with low-dose
rivaroxaban, without any hemorrhagic complications. Although
rivaroxaban has only been approved recently and its efﬁcacy is
not as well documented as that of warfarin, it might be useful for
the treatment of DVT and PE, especially in patients with warfarin
allergy.
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